🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

UHS stock soars to all-time high of $220.79 amid robust growth

Published 08/13/2024, 09:34 AM
UHS
-

Universal Health Services , Inc. (NYSE:UHS) has reached an all-time high, with its stock price soaring to $220.79. This milestone underscores a period of significant growth for the healthcare service provider, reflecting investor confidence and a bullish outlook on the company's performance. Over the past year, UHS has witnessed an impressive 65.61% change in its stock value, a testament to its resilience and strategic initiatives that have resonated well with the market. The company's ability to achieve this record-setting price level highlights its strong operational execution and the increasing demand for healthcare services, positioning UHS favorably in the competitive industry landscape.

In other recent news, Universal Health Services has seen a wave of analyst upgrades and target price adjustments. Mizuho Securities reaffirmed an Outperform rating on the company's shares, raising the target price to $240, following a period of significant growth and margin expansion. The firm also highlighted the company's solid adjusted admissions trends and robust adjusted EBITDA growth. Universal Health Services' preliminary expectations for revenue from a new supplemental payment program in Washington, D.C. further contributed to this positive outlook.

BofA Securities, UBS, and Cantor Fitzgerald also upgraded Universal Health Services' stock, citing potential for significant earnings growth. BofA Securities raised its price target for the company's shares to $235, maintaining a Buy rating, following a positive guidance update from the company. UBS upgraded the company's stock from Neutral to Buy, raising the price target to $226, reflecting a positive outlook on the company's earnings potential, particularly in its behavioral health services. Cantor Fitzgerald upgraded the company's stock from Underweight to Neutral and raised its price target to $219, citing an optimistic outlook for the company's acute care segment.

Additionally, TD Cowen raised the stock price target to $220 from the previous figure of $183, maintaining a Hold rating on the stock. The firm highlighted the potential for new Service Delivery Programs (SDP) in Tennessee and Washington D.C., which could contribute more than $120 million annually to the company's revenue, should they receive approval.

Lastly, Universal Health Services declared a cash dividend of $0.20 per share, scheduled for disbursement in June, demonstrating its commitment to delivering value to shareholders.

InvestingPro Insights

Universal Health Services, Inc. (UHS) has not only hit a record stock price but also presents a compelling case for investors according to InvestingPro data and tips. The company's market capitalization stands at $14.59 billion, underscoring its significant presence in the healthcare sector. With a P/E ratio of 15.73, UHS trades at an attractive valuation, especially when considering its near-term earnings growth. This is further supported by a PEG ratio of 0.38, indicating potential undervaluation relative to earnings growth expectations.

InvestingPro Tips reveal that UHS management has been actively buying back shares, a sign of confidence in the company's value. Furthermore, 12 analysts have recently revised their earnings estimates upwards for the upcoming period, suggesting that the company's financial prospects are on the rise. Additionally, UHS has maintained dividend payments for 22 consecutive years, demonstrating a commitment to returning value to shareholders.

For investors seeking more detailed analysis and additional insights, InvestingPro offers a total of 12 tips for UHS, which can be accessed through their platform. With a track record of high returns over the past year and trading near its 52-week high, UHS's stock performance and fundamentals make it a noteworthy candidate for investment consideration. The next earnings date is set for October 23, 2024, which will provide further clarity on the company's trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.